Edesa Biotech Inc

NASDAQ:EDSAUnited States

Edesa Biotech, Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on inflammatory and immune-related diseases. The Company's two lead product candidates, EB05 and EB01, are in later stage clinical studies. EB05 is a monoclonal antibody therapy, developing as a treatment for acute respiratory distress syndrome (ARDS), a life-threatening form of respiratory failure. ARDS can be caused by viral diseases, including Covid-19, bacterial pneumonia, sepsis, chest injury and other causes. Specifically, EB05 inhibits toll-like receptor 4 (TLR4), an immune signaling protein and an important mediator of inflammation that has been shown to be activated by SARS-COV2 as well as other respiratory infections, such as influenza. In addition to EB05, the Company is also developing an sPLA2 inhibitor, designated as EB01, as a topical treatment for chronic allergic contact dermatitis (ACD), a common, potentially debilitating condition and occupational illness.

Contact Information

Headquarters

100 Spy CrtMARKHAM, ON, Canada L3R 5H6

Phone

905-475-1234

Fax

905-475-1234

Executives

Independent Chairman of the Board

Sean Macdonald

President

Michael Brooks

Chief Executive Officer, Corporate Secretary and Director

Pardeep Nijhawan

Chief Financial Officer

Kathi Niffenegger

Director

Jennifer Chao